This was revealed in a recent study at Tours University Hospital conducted by urology doctor Hugo Crespin. with an increase of +104% in Guadeloupe; and +73% in Martinique, two islands particularly affected by this increase in prostate cancer cases. The study also shows that mortality rates were higher in certain regions during this period.
•
From the beginning, the study conducted by the CHRU of Tours underlines this, en 2015, prostate cancer ranked first among cancer incidence and was the third cause of death in men in France, according to the Center for Epidemiology on Medical Causes of Death (CépiDc) – INSERM, with unexplained excess mortality in some regions.
Between 2010 and 2021, 564,975 new cases of prostate cancer were diagnosed, with an average annual increase of 47,081 cases. All-cause mortality was 20,259 deaths per year, of which 7,265 were specific to prostate cancer.
The mean age at diagnosis was 70.1 years ± 9.6 years while at death from all causes was 80.2 years ± 9.7 years.
An increase in both prevalence and incidence over the past decade from 2010 to 2020 is a significant trend.
Dr Hugo Crespin, urologist (CHRU of Tours) and author of the study.
And Dr. A study led by Crespin shows a certain reality: a special mortality rate for prostate cancer has also been observed, from + 10% to + 46% in regions such as Normandy, Hautes-de-France, Brittany, Centre-Val. De Loire and DROMs compared to national averages.
For Brittany, Hauts-de-France and Martinique, specific excess mortality from prostate cancer persists even after adjusting for population characteristics, suggesting a regional effect.
This raises questions about environmental or maintenance factors in these regions. Agricultural databases show possible link with prostate cancer risk. Mortality associated with access to generic medicine is more complex, with protective effects in overall mortality and deleterious effects particularly with regard to metastatic prostate cancer.
Hugo Crespin, urologist (CHRU of Tours) and author of the study.
An increase of +104% in Guadeloupe, which can be explained by several factors, according to Laurent Bruro, University Professor of Urology at the Guadeloupe University Hospital. Prevention and aging will be the causes of this acute increase, so we should not forget that, if caught in time, this cancer can be cured.
On the treatment side, the advances are quite remarkable. Protocols are increasingly mastered, especially for local forms or radiotherapy, and surgery yields good results.
See also: Prostate: what treatment in Guadeloupe
